Shanghai Fosun Pharmaceutical Group Co (600196.SS) Stock Price

Shanghai Fosun Pharmaceutical Group Co Price

🇨🇳SSE·CLOSED
22.14CNY
Market closed
Today +/-
Today %

Shanghai Fosun Pharmaceutical Group Co (600196.SS) Stock | ISIN CNE000000X38. The current Shanghai Fosun Pharmaceutical Group Co stock price is 22.14 CNY (2026). Revenue is 44.24 B CNY. Net income is 4.15 B CNY. The P/E ratio is 14.26. Market capitalization is 59.12 B CNY. Shanghai Fosun Pharmaceutical Group Co operates in the Health sector.

Shanghai Fosun Pharmaceutical Group Co stock price

Ex-Dividend
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Shanghai Fosun Pharmaceutical Group Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Shanghai Fosun Pharmaceutical Group Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Shanghai Fosun Pharmaceutical Group Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Shanghai Fosun Pharmaceutical Group Co Stock Price History
DateShanghai Fosun Pharmaceutical Group Co Price
Access this data via the Eulerpool API

Shanghai Fosun Pharmaceutical Group Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2005
2.99 B CNY
143 M CNY
159 M CNY
Jan 1, 2006
4.08 B CNY
92 M CNY
258 M CNY
Jan 1, 2007
3.69 B CNY
164 M CNY
626 M CNY
Jan 1, 2008
3.77 B CNY
118 M CNY
691 M CNY
Jan 1, 2009
3.87 B CNY
157 M CNY
2.5 B CNY
Jan 1, 2010
4.56 B CNY
163 M CNY
864 M CNY
Jan 1, 2011
6.49 B CNY
324 M CNY
1.17 B CNY
Jan 1, 2012
7.34 B CNY
553 M CNY
1.56 B CNY
Jan 1, 2013
10 B CNY
1.03 B CNY
1.58 B CNY
Jan 1, 2014
12.03 B CNY
1.11 B CNY
2.11 B CNY
Jan 1, 2015
12.61 B CNY
1.36 B CNY
2.46 B CNY
Jan 1, 2016
14.63 B CNY
1.64 B CNY
2.81 B CNY
Jan 1, 2017
18.53 B CNY
2.24 B CNY
3.12 B CNY
Jan 1, 2018
24.92 B CNY
2.29 B CNY
2.71 B CNY
Jan 1, 2019
28.59 B CNY
2.49 B CNY
3.32 B CNY

Shanghai Fosun Pharmaceutical Group Co Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 10, 2026, 6:24 PM
 
REVENUE (M CNY)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M CNY)
NET INCOME (M CNY)
NET INCOME GROWTH (%)
DIV. (CNY)
DIV. GROWTH (%)
SHARES (M)
DOCUMENTS
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Shanghai Fosun Pharmaceutical Group Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Shanghai Fosun Pharmaceutical Group Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Shanghai Fosun Pharmaceutical Group Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Shanghai Fosun Pharmaceutical Group Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Shanghai Fosun Pharmaceutical Group Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Shanghai Fosun Pharmaceutical Group Co stock margins

The Shanghai Fosun Pharmaceutical Group Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Shanghai Fosun Pharmaceutical Group Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Shanghai Fosun Pharmaceutical Group Co.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2005
29.98 %
4.78 %
5.32 %
Jan 1, 2006
21.34 %
2.25 %
6.32 %
Jan 1, 2007
26.59 %
4.44 %
16.95 %
Jan 1, 2008
27.67 %
3.13 %
18.31 %
Jan 1, 2009
32.02 %
4.05 %
64.51 %
Jan 1, 2010
33.9 %
3.58 %
18.97 %
Jan 1, 2011
37.63 %
5 %
17.98 %
Jan 1, 2012
43.62 %
7.53 %
21.31 %
Jan 1, 2013
44.22 %
10.3 %
15.84 %
Jan 1, 2014
43.87 %
9.19 %
17.57 %
Jan 1, 2015
49.78 %
10.81 %
19.51 %
Jan 1, 2016
53.81 %
11.23 %
19.18 %
Jan 1, 2017
58.84 %
12.06 %
16.86 %
Jan 1, 2018
58.34 %
9.17 %
10.87 %
Jan 1, 2019
59.57 %
8.71 %
11.62 %

Shanghai Fosun Pharmaceutical Group Co Stock Revenue, EBIT, Earnings per Share

The Shanghai Fosun Pharmaceutical Group Co earnings per share therefore indicates how much revenue Shanghai Fosun Pharmaceutical Group Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2005
1.84 CNY
0.09 CNY
0.1 CNY
Jan 1, 2006
2.2 CNY
0.05 CNY
0.14 CNY
Jan 1, 2007
1.99 CNY
0.09 CNY
0.34 CNY
Jan 1, 2008
2.03 CNY
0.06 CNY
0.37 CNY
Jan 1, 2009
2.09 CNY
0.08 CNY
1.35 CNY
Jan 1, 2010
2.42 CNY
0.09 CNY
0.46 CNY
Jan 1, 2011
3.41 CNY
0.17 CNY
0.61 CNY
Jan 1, 2012
3.28 CNY
0.25 CNY
0.7 CNY
Jan 1, 2013
4.46 CNY
0.46 CNY
0.71 CNY
Jan 1, 2014
5.24 CNY
0.48 CNY
0.92 CNY
Jan 1, 2015
5.43 CNY
0.59 CNY
1.06 CNY
Jan 1, 2016
6.28 CNY
0.71 CNY
1.2 CNY
Jan 1, 2017
7.53 CNY
0.91 CNY
1.27 CNY
Jan 1, 2018
9.88 CNY
0.91 CNY
1.07 CNY
Jan 1, 2019
11.15 CNY
0.97 CNY
1.3 CNY

Shanghai Fosun Pharmaceutical Group Co business model & stock analysis

Shanghai Fosun Pharmaceutical Group Co Ltd is a Chinese company specializing in the healthcare industry. It was founded in 1994 and is headquartered in Shanghai. The company has grown to become one of the largest pharmaceutical conglomerates in China and operates internationally. The company's history began in the 1990s with the establishment of Shanghai Fosun High-Tech (Group) Co. Ltd. Through the acquisition of local pharmaceutical companies, Fosun quickly secured a place among the major players in the Chinese pharmaceutical market. From the beginning, the development, production, and marketing of pharmaceutical products and medical devices were the main focus. Today, Shanghai Fosun Pharmaceutical is a holding company with various subsidiaries operating in different areas of medicine. These include the development of innovative drugs, the production of generic drugs, and the business-to-consumer sector. The company generates an annual revenue of over six billion US dollars. One of Shanghai Fosun Pharmaceutical's most well-known products is the drug Alunbrig for the treatment of lung cancer. It is a tyrosine kinase inhibitor that inhibits the growth of cancer cells. Alunbrig has shown good results in clinical studies and is now approved for the treatment of lung cancer in many countries. Another important business area for Shanghai Fosun Pharmaceutical is the production of generic drugs. These are imitations of already approved, often expensive, original drugs. Fosun manufactures such medications at a significantly lower cost than the original manufacturer, making them more accessible to a broader population. In addition to drug development and generic production, Shanghai Fosun Pharmaceutical is also active in other areas of the healthcare industry. In recent years, the company has acquired several private hospitals in China and operates them under the name Fosun International Hospitals. Special emphasis is placed on state-of-the-art medical technology and patient-oriented care. Another important area is the manufacturing of medical devices. Shanghai Fosun Pharmaceutical works closely with partners from both domestic and foreign markets to develop innovative products. An example is the artificial hip joint, which was developed in collaboration with an American partner company. Fosun produces and distributes over 70 different types of medical devices. In summary, Shanghai Fosun Pharmaceutical Group is an innovative company specializing in various areas of the healthcare industry. Through its consistent focus on growth and innovation, Fosun has steadily expanded in recent years and has become one of the key players in the Chinese pharmaceutical market. However, the global expansion and ambitious goals also leave room for risks and mistakes.

Shanghai Fosun Pharmaceutical Group Co SWOT Analysis

Strengths

Shanghai Fosun Pharmaceutical Group Co Ltd possesses several key strengths that give it a competitive advantage:

  • 1. Strong Market Presence: Shanghai Fosun Pharmaceutical is a well-established player in the pharmaceutical industry with a significant market share in China and a growing presence in international markets.
  • 2. Diverse Product Portfolio: The company offers a wide range of pharmaceutical products, including prescription drugs, over-the-counter medications, and biopharmaceuticals, catering to various therapeutic areas.
  • 3. Research and Development Capabilities: Shanghai Fosun Pharmaceutical has a dedicated research and development team focused on innovation, new drug discovery, and technology advancements.
  • 4. Strong Financial Performance: The company has consistently delivered strong financial results, with steady revenue growth and healthy profit margins.
  • 5. Strategic Partnerships: Shanghai Fosun Pharmaceutical has established collaborations with leading global pharmaceutical companies, enabling access to new markets, technologies, and expertise.

Weaknesses

Despite its strengths, Shanghai Fosun Pharmaceutical Group Co Ltd also faces certain weaknesses that need to be addressed:

  • 1. Dependence on Domestic Market: The company is heavily reliant on the Chinese market, which exposes it to regulatory uncertainties, market fluctuations, and intense competition within the country.
  • 2. Limited International Presence: While the company has made efforts to expand globally, its international operations remain relatively modest compared to its domestic business.
  • 3. Product Quality Concerns: There have been instances of product quality issues in the past, which negatively impacted the company's reputation and raised concerns among consumers and regulatory authorities.
  • 4. Integration Challenges: Shanghai Fosun Pharmaceutical has undergone several acquisitions and mergers, leading to integration challenges and potential disruptions in business operations.

Opportunities

Shanghai Fosun Pharmaceutical Group Co Ltd can capitalize on the following opportunities to further enhance its growth prospects:

  • 1. Growing Healthcare Industry: The global healthcare market is expanding rapidly, presenting opportunities for Shanghai Fosun Pharmaceutical to expand its presence and penetrate new markets.
  • 2. Aging Population and Chronic Diseases: With the increasing prevalence of chronic diseases and aging population, there is a rising demand for pharmaceutical products and healthcare services, creating a favorable market environment for the company.
  • 3. Innovation and Technology Advancements: Advancements in healthcare technologies, such as precision medicine, gene therapy, and digital health solutions, open avenues for Shanghai Fosun Pharmaceutical to develop innovative products and services.
  • 4. Strategic Collaborations: The company can explore strategic partnerships or collaborations with research institutions, universities, and other industry players to leverage expertise, access new technologies, and enhance its product pipeline.

Threats

Shanghai Fosun Pharmaceutical Group Co Ltd must be mindful of the following threats that could potentially impact its business:

  • 1. Intense Competition: The pharmaceutical industry is highly competitive, with numerous domestic and international players vying for market share, which may lead to price wars and margin squeeze.
  • 2. Stringent Regulatory Environment: Compliance with stringent regulations and evolving regulatory frameworks adds complexities and costs to the company's operations.
  • 3. Pricing Pressure: Government initiatives to control healthcare costs, pricing challenges in emerging markets, and reimbursement policies can exert pressure on the company's pricing and profit margins.
  • 4. Intellectual Property Risks: Intellectual property theft, counterfeit products, and patent expirations pose risks to Shanghai Fosun Pharmaceutical's proprietary drugs and potential loss of market exclusivity.

Shanghai Fosun Pharmaceutical Group Co Eulerpool Fair Value

Shanghai Fosun Pharmaceutical Group Co historical P/E ratio, EBIT multiple, and P/S ratio

Shanghai Fosun Pharmaceutical Group Co annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Shanghai Fosun Pharmaceutical Group Co shares outstanding

The number of shares was Shanghai Fosun Pharmaceutical Group Co in 2025 — This indicates how many shares 2.67 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2005
1.62 B base_Shares
Jan 1, 2006
1.86 B base_Shares
Jan 1, 2007
1.86 B base_Shares
Jan 1, 2008
1.86 B base_Shares
Jan 1, 2009
1.86 B base_Shares
Jan 1, 2010
1.89 B base_Shares
Jan 1, 2011
1.9 B base_Shares
Jan 1, 2012
2.24 B base_Shares
Jan 1, 2013
2.24 B base_Shares
Jan 1, 2014
2.3 B base_Shares
Jan 1, 2015
2.32 B base_Shares
Jan 1, 2016
2.33 B base_Shares
Jan 1, 2017
2.46 B base_Shares
Jan 1, 2018
2.52 B base_Shares
Jan 1, 2019
2.56 B base_Shares

Shanghai Fosun Pharmaceutical Group Co Dividend History

25 years of dividend payments

YearAnnual DividendYoY ChangePayments
20250.32CNY 18.5%
Aug 4, 20250.32CNY 18.5%1/1
20240.27CNY 35.7%
20230.42CNY 25.0%
20220.56CNY 30.2%
20210.43CNY 10.3%
20200.39CNY 21.9%
20190.32CNY 15.8%
20180.38CNY 8.6%
20170.35CNY 9.4%
20160.32CNY 14.3%

Shanghai Fosun Pharmaceutical Group Co dividend history and estimates

In 2025, Shanghai Fosun Pharmaceutical Group Co paid a dividend amounting to 0.32 CNY. Dividend means that Shanghai Fosun Pharmaceutical Group Co distributes a portion of its profits to its owners.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Special dividend
Jan 1, 2005
0.15 CNY
0 CNY
0 CNY
Invalid Date
0 CNY
0.34 CNY
0.26 CNY
Jan 1, 2007
0.08 CNY
0 CNY
0 CNY
Jan 1, 2008
0.1 CNY
0 CNY
0 CNY
Jan 1, 2009
0.1 CNY
0 CNY
0 CNY
Jan 1, 2010
0.07 CNY
0 CNY
0 CNY
Jan 1, 2011
0.1 CNY
0 CNY
0 CNY
Jan 1, 2012
0.1 CNY
0 CNY
0 CNY
Invalid Date
0.21 CNY
0.21 CNY
0 CNY
Invalid Date
0.27 CNY
0.27 CNY
0 CNY
Invalid Date
0.28 CNY
0.28 CNY
0 CNY
Invalid Date
0.32 CNY
0.32 CNY
0 CNY
Jan 1, 2017
0.35 CNY
0 CNY
0 CNY
Jan 1, 2018
0.38 CNY
0 CNY
0 CNY
Jan 1, 2019
0.32 CNY
0 CNY
0 CNY

Shanghai Fosun Pharmaceutical Group Co dividend payout ratio

In 2025, Shanghai Fosun Pharmaceutical Group Co had a payout ratio of 33.27%. The payout ratio indicates the percentage of the company's profits that Shanghai Fosun Pharmaceutical Group Co distributes as dividends.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2005
115.4 %
Jan 1, 2006
186.79 %
Jan 1, 2007
15.08 %
Jan 1, 2008
18.02 %
Jan 1, 2009
4.94 %
Jan 1, 2010
14.49 %
Jan 1, 2011
16.39 %
Jan 1, 2012
14.29 %
Jan 1, 2013
29.58 %
Jan 1, 2014
29.35 %
Jan 1, 2015
26.42 %
Jan 1, 2016
26.67 %
Jan 1, 2017
27.56 %
Jan 1, 2018
35.51 %
Jan 1, 2019
24.62 %
Price targets and forecasts for Shanghai Fosun Pharmaceutical Group Co are not yet available.

EESG©

Eulerpool ESG Scorecard© for the Shanghai Fosun Pharmaceutical Group Co stock

95/100
99
Environment
99
Social
86
Governance
E

Environment

20
Scope 1 - Direct Emissions184,016
Scope 2 - Indirect emissions from purchased energy653,644
Scope 3 - Indirect emissions within the value chain91,775
Total CO₂ emissions837,660
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees50.268
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Shanghai Fosun Pharmaceutical Group Co shareholder structure

% Name
33.32415%
Shanghai Fosun High Technology (Group) Co., Ltd.
Shanghai Fosun High Technology (Group) Co., Ltd.
1.45057%
China Securities Finance Corporation Limited
China Securities Finance Corporation Limited
1.38985%
E Fund Management Co. Ltd.
E Fund Management Co. Ltd.
0.86122%
China Merchants Fund Management Co. Ltd.
China Merchants Fund Management Co. Ltd.
0.78132%
Huatai-PineBridge Fund Management Co., Ltd.
Huatai-PineBridge Fund Management Co., Ltd.
0.59679%
Yinhua Fund Management Co., Ltd.
Yinhua Fund Management Co., Ltd.
0.50779%
Xiong (Liwu)
Xiong (Liwu)
0.39893%
China Asset Management Co., Ltd.
China Asset Management Co., Ltd.
0.3954%
Tianhong Asset Management Co., Ltd.
Tianhong Asset Management Co., Ltd.
0.38285%
China Universal Asset Management Co., Ltd.
China Universal Asset Management Co., Ltd.
...

Shanghai Fosun Pharmaceutical Group Co Executives and Management Board

KW

Mr. Kexin Wang

(59)

Executive Co-Chairman of the Board · since 2011

Compensation15.09 M CNY
YW

Mr. Yifang Wu

(54)

Executive Chairman of the Board · since 2016

Compensation12 M CNY
WZ

Mr. Wenjie Zhang

(57)

Executive President, Co-CEO - Innovative Drugs Division

Compensation11.63 M CNY
DW

Mr. Deyong Wen

(52)

Chief Executive Officer, Executive Director · since 2016

Compensation9.83 M CNY
XG

Ms. Xiaohui Guan

(53)

Executive Vice Chairman of the Board · since 2016

Compensation8.97 M CNY

Frequently asked questions about Shanghai Fosun Pharmaceutical Group Co

The business model of Shanghai Fosun Pharmaceutical Group Co Ltd focuses on various aspects of the pharmaceutical industry. As a leading healthcare company, it engages in research and development, manufacturing, sales, and distribution of pharmaceutical products. Shanghai Fosun Pharmaceutical Group Co Ltd is committed to promoting innovation and improving the accessibility of healthcare products and services. It operates through segments such as pharmaceutical manufacturing, research and development, distribution and retail, and medical services. By leveraging its strong industry expertise and strategic partnerships, Shanghai Fosun Pharmaceutical Group Co Ltd aims to contribute to the advancement of healthcare and provide high-quality medical solutions to customers worldwide.